Vaxart

Vaxart, Inc. operates as a clinical-stage biotechnology company, which engages in the development of oral recombinant vaccines based on its Vector-Adjuvant-Antigen Standardized Technology (VAAST) oral vaccine platform. Its investigational vaccines are administered using a room temperature-stable tablet, rather than by injection. It is developing prophylactic vaccine candidates that target a range of infectious diseases, including SARS-CoV-2, norovirus, seasonal influenza and respiratory syncytial virus (RSV). The company was founded in 2004 and is headquartered in South San Francisco, CA.

Earnings data Q1 2021

Earnings data Q2 2021

Earnings data Q3 2021

Earnings data Q4 2021

Earnings data Q1 2022

Earnings data Q2 2022

Earnings data Q3 2022

Earnings data Q4 2022

Earnings data Q1 2023

Earnings data Q2 2023

Earnings data Q3 2023

Earnings data Q4 2023

Earnings data Q1 2024

Earnings data Q2 2024

Earnings data Q3 2024

Earnings data Q4 2024

Vaxart reports solid Q1 earnings, progresses in vaccine development

Vaxart's Q1 2024 performance reflects financial stability and progress in vaccine development, particularly with positive Phase I trial results for their norovirus vaccine.
While the company faces challenges in funding, manufacturing, and program prioritization, opportunities lie in advancing COVID-19 vaccine trials and regulatory engagements.
By addressing concerns and leveraging opportunities effectively, Vaxart can strengthen its position in the vaccine market and drive future growth and innovation.

Vaxart reports strong Q3 revenue, advances in COVID and norovirus

Vaxart's Q3 2024 earnings call highlighted revenue from government contracts, progress in COVID, norovirus, and HPV programs, and promising trial data.
The company faces challenges in study enrollment, resource allocation, and regulatory compliance but remains open to collaborations and global vaccine development.
With a cash runway into 2026, Vaxart is well-positioned to leverage market demand for their oral pill vaccine candidates and drive future growth.
Strong performance, constructive FDA feedback, and market opportunities position Vaxart for continued success in vaccine development and partnerships.

Revenue

Cost of revenue

Gross profit

Operating expenses

SG&A

Other

Operating income

EBITDA

Net income

Earnings per share

Total assets

Current assets

Cash & equivalents

Receivables

Inventory

Non-current assets

Net PPE

Intangibles

Total liabilities

Current liabilities

Short term debt

Income tax payable

Non-current liabilities

Long-term debt

Total equity

Stockholders equity

Minority interest

Total liabilities & equity

Total debt

Net debt

Book value per share

Cash from operations

Funds from operations

Change in working capital

Cash from investing

Capital expenditure

Purchase/sale of investments

Purchase/sale of business

Other sources

Cash from financing

Change in stock

Change in debt

Cash dividends paid

Cash from other sources

Net change in cash

Free cash flow

Vaxart, Inc. operates as a clinical-stage biotechnology company, which engages in the development of oral recombinant vaccines based on its Vector-Adjuvant-Antigen Standardized Technology oral vaccine platform. Its investigational vaccines are administered using a room temperature-stable tablet, rather than by injection. It is developing prophylactic vaccine candidates that target a range of infectious diseases, including SARS-CoV-2, norovirus, seasonal influenza and respiratory syncytial virus (RSV). The company was founded in March 2004 and is headquartered in South San Francisco, CA.

VAXART, INC. (VXRT) reached a significant support level, and could be a good pick for investors from a technical perspective.

VAXART, INC. (VXRT) Now Trades Above Golden Cross: Time to Buy?

—  Data served as foundation for current vaccine candidate for planned Phase 2 research —  Vaxart vaccine candidates elicited strong antigen-specific serum IgG and IgA with neutralizing activity against multiple variants of concern —  Vaccination reduced SARS-CoV-2 shedding following infectious challenge in both the upper and lower airway of non-human primates SOUTH SAN FRANCISCO, Calif., Feb. 05, 2024 (GLOBE NEWSWIRE) -- Vaxart, Inc. (Nasdaq: VXRT) today announced the publication of preclinical non-human primate data demonstrating the potential of its COVID-19 vaccine to protect against multiple SARS-CoV-2 variants of concern (VOC)s.

Vaxart Announces Publication in Vaccines of Non-Human Primate Preclinical Data Demonstrating Its Next-Generation Vaccine Candidates Elicit Mucosal and Systemic Immunogenicity and Reduce Viral Shedding after SARS-CoV-2 Challenge

- 10,000-subject Phase 2b study would evaluate Vaxart's next generation oral pill XBB COVID-19 vaccine against an approved mRNA vaccine comparator -

Vaxart Receives $9.27 Million BARDA Project NextGen Award to Prepare for Phase 2b Clinical Study Evaluating Its COVID-19 Oral Pill Vaccine Candidate

SOUTH SAN FRANCISCO, Calif., Jan. 16, 2024 (GLOBE NEWSWIRE) -- Vaxart, Inc. (Nasdaq: VXRT) today announced that it has entered into a common stock purchase agreement with RA Capital Management for the sale of 15,384,615 shares of its common stock in a registered direct offering at an offering price of $0.65 per share.

Vaxart Announces $10.0 Million Registered Direct Offering with RA Capital Management

Chief Executive Officer Andrei Floroiu Resigns Chair Michael J. Finney, Ph.D.

Vaxart, Inc. Announces Management Change

On track to report topline data by the end of 2024 SOUTH SAN FRANCISCO, Calif., Dec. 21, 2023 (GLOBE NEWSWIRE) -- Vaxart, Inc. (Nasdaq: VXRT) today announced that it has completed enrollment and dosing in the Phase 1 clinical trial evaluating Vaxart's oral pill bivalent norovirus vaccine candidate focused on lactating mothers.

Vaxart Announces Last Subject Dosed in Phase 1 Trial of Its Norovirus Vaccine Candidate in Lactating Mothers

Vaxart, Inc. (NASDAQ:VXRT ) Q3 2023 Earnings Conference Call November 2, 2023 4:30 PM ET Company Participants Andrei Floroiu - President and CEO James Cummings - Chief Medical Officer Phil Lee - CFO Brant Biehn - SVP and Business Operations Edward Berg - Senior Vice President and General Counsel Conference Call Participants Mayank Mamtani - B. Riley Securities Liang Cheng - Jefferies Operator Greetings, and welcome to the Vaxart Business Update and Third Quarter 2023 Financial Results Conference Call.

Vaxart, Inc. (VXRT) Q3 2023 Earnings Call Transcript

Norovirus challenge study topline results indicate the potential of Vaxart's oral pill vaccine candidate to reduce rates of norovirus infection, norovirus acute gastroenteritis and viral shedding

Vaxart Provides Business Update and Reports Third Quarter 2023 Financial Results

SOUTH SAN FRANCISCO, Calif., Oct. 11, 2023 (GLOBE NEWSWIRE) -- Vaxart, Inc. (Nasdaq: VXRT) today announced that Dr. Sean Tucker, Founder and Chief Scientific Officer, and Dr. James F. Cummings, Chief Medical Officer, will present at the World Vaccine Congress Europe 2023 in Barcelona, Spain on Wednesday, October 18 and Thursday, October 19, 2023.

Vaxart to Present at World Vaccine Congress Europe 2023 on October 18-19

Abeona Therapeutics

CRISPR Therapeutics

Investing in biotech stock can provide investors with immense rewards but also substantial risks. The key is finding the right balance.

3 Biotech Blockbusters to Turn $5,000 Into $50,000

After losing some value lately, a hammer chart pattern has been formed for VAXART, INC. (VXRT), indicating that the stock has found support.

Bears are Losing Control Over VAXART, INC. (VXRT), Here's Why It's a 'Buy' Now

Start Time: 16:30 January 1, 0000 5:01 PM ET Vaxart, Inc. (NASDAQ:VXRT ) Q2 2023 Earnings Conference Call August 03, 2023, 16:30 PM ET Company Participants Andrei Floroiu - President and CEO James Cummings - Chief Medical Officer Sean Tucker - SVP and Chief Scientific Officer Phil Lee - CFO Brant Biehn - SVP and Business Operations Conference Call Participants Charles Duncan - Cantor Fitzgerald Mayank Mamtani - B. Riley Securities Operator Greetings, and welcome to the Vaxart Business Update and Second Quarter 2023 Financial Results Conference Call.

Vaxart, Inc. (VXRT) Q2 2023 Earnings Call Transcript

VAXART, INC. (VXRT) came out with a quarterly loss of $0.16 per share versus the Zacks Consensus Estimate of a loss of $0.19.

VAXART, INC. (VXRT) Reports Q2 Loss, Tops Revenue Estimates

On track to report topline data from Phase 2 GI.1 norovirus vaccine challenge study in Q3 2023 Cash runway extended into Q3 2024 Conference call today at 4:30 p.m. ET SOUTH SAN FRANCISCO, Calif.

Vaxart Provides Business Update and Reports Second Quarter 2023 Financial Results

SOUTH SAN FRANCISCO, Calif., June 26, 2023 (GLOBE NEWSWIRE) -- Vaxart, Inc. (Nasdaq: VXRT) today held its Annual Meeting of Shareholders in a virtual-only format. Preliminary results from the Annual Meeting indicate that all four proposals were approved by Vaxart shareholders.

Vaxart Stockholders Approve All Four Proposals in the 2023 Proxy Statement

SOUTH SAN FRANCISCO, Calif., June 21, 2023 (GLOBE NEWSWIRE) -- Vaxart, Inc. (Nasdaq: VXRT) today encourages its stockholders of record on April 28, 2023, to vote on its proxy if they have not yet done so. The Company urges a yes vote on all Proxy proposals. Leading proxy advisors ISS and Glass Lewis are both advising shareholders to vote in favor of all proposals.

Vaxart Encourages All Stockholders of Record as of April 28, 2023 to Vote by June 25, 2023, at 11:59 p.m. ET

Vaxart (NASDAQ: VXRT ) stock is taking a beating on Wednesday as investors react to the company announcing a proposed public share offering. According to a press release from Vaxart, the company is holding that public offering today.

Why Is Vaxart (VXRT) Stock Down 25% Today?

SOUTH SAN FRANCISCO, Calif., June 07, 2023 (GLOBE NEWSWIRE) -- Vaxart, Inc. (Nasdaq: VXRT) today announced the pricing of its underwritten public offering of 16,000,000 shares of its common stock, for gross proceeds of approximately $15,000,000, before deducting the underwriting discounts and commissions and other estimated offering expenses payable by Vaxart. The offering is expected to close on or about June 9, 2023, subject to customary closing conditions. In addition, Vaxart has granted to the underwriter a 30-day option to purchase up to 2.4 million additional shares of its common stock.

Vaxart, Inc. Announces Pricing of $15,000,000 Public Offering of Common Stock

SOUTH SAN FRANCISCO, Calif., June 06, 2023 (GLOBE NEWSWIRE) -- Vaxart, Inc. (Nasdaq: VXRT) today announced that it has commenced an underwritten public offering of its common stock. In addition, Vaxart expects to grant to the underwriter a 30-day option to purchase up to an additional 15% of shares of the common stock sold in the public offering. All of the securities in the offering are to be sold by Vaxart. The offering is subject to market and other customary closing conditions, and there can be no assurance as to whether or when the offering may be completed, or as to the actual size or terms of the offering.

Vaxart, Inc. Announces Proposed Public Offering of Common Stock

Vaxart, Inc. (NASDAQ:VXRT ) Q1 2023 Earnings Conference Call May 4, 2023 4:30 PM ET Company Participants Edward Berg - Senior Vice President and General Counsel Andrei Floroiu - Chief Executive Officer James Cummings - Chief Medical Officer Sean Tucker - Founder & Chief Scientific Officer Phil Lee - Chief Financial Officer Conference Call Participants Mayank Mamtani - B. Riley Securities Roger Song - Jefferies Operator Greetings and welcome to Vaxart Business Update and First Quarter 2023 Financial Results Conference Call.

Vaxart, Inc. (VXRT) Q1 2023 Earnings Call Transcript

On track to report key top line data from two Phase 2 norovirus vaccine studies mid-year and in Q3 2023 Continue to anticipate cash runway into Q2 2024 Conference call today at 4:30 p.m. ET SOUTH SAN FRANCISCO, Calif.

Vaxart Provides Business Update and Reports First Quarter 2023 Financial Results

Company to provide a detailed overview of its norovirus clinical program

Vaxart to Host Webcast with Key Opinion Leaders to Discuss the Health Impact and Disease Burden for Norovirus

Vaxart, Inc. (NASDAQ:VXRT ) Q4 2022 Earnings Conference Call March 15, 2023 4:30 PM ET Company Participants Brant Biehn - Senior Vice President, Business Operations Andrei Floroiu - Chief Executive Officer James Cummings - Chief Medical Officer Sean Tucker - Founder & Chief Scientific Officer Phil Lee - Chief Financial Officer Conference Call Participants Charles Duncan - Cantor Fitzgerald Mayank Mamtani - B. Riley Securities Operator Greetings.

Vaxart, Inc. (VXRT) Q4 2022 Earnings Call Transcript

Prioritizing oral bivalent norovirus candidate, one of the most advanced norovirus vaccines in development

News for Vaxart Stock (VXRT)